Courtagefri handel på Nordnet till sista juni 2027! Har du inget konto på Nordnet så är det verkligen läge att skaffa ett. Just nu får nya kunder courtagefri handel till sista juni 2027. Läs mer om erbjudandet och skapa ditt konto här
Erbjudandet gäller nya kunder och omfattar handel via Nordnets app eller hemsida i nordiska aktier, ETF:er, teckningsrätter och teckningsoptioner. För fullständiga villkor se nordnet.se/jubileum. Kom ihåg att investeringar alltid innebär en risk.

I-Tech announces a one year extension of the current EU Approval for Selektope (Medetomidine)

I-Tech AB, developers of the innovative antifouling technology Selektope, announce that the current approval for Selektope (Medetomidine) in the European Union has been extended by one year. This extension is part of the normal procedures as the EU Commission continues its thorough re-registration process.

The re-registration process in the EU involves a comprehensive review to ensure that all substances meet stringent safety and environmental standards. As part of this process, a public consultation was conducted, during which I-Tech received substantial support from various stakeholders. This positive feedback underscores the confidence in Selektope's efficacy and safety.

While the EU Commission's decision is taking longer than initially anticipated, I-Tech views this extension positively.

I-Tech´s CEO, Markus Jönsson comments:

“The new extension reflects the importance of a well-considered decision that takes into account all public consultation opinions. We believe that this careful approach will ultimately benefit both the environment and the maritime industry. We keep working actively on informing decision makers and interest groups about why Selektope is important for use in the EU and we stay hopeful that member states will reach a positive decision by the end of 2025.”